BioSpace News Archive

ZERO and Bayer – two leaders in prostate cancer – take on one of the most common cancers in American men .

Diamond Therapeutics Inc. is pleased to announce the selection of BioPharma Services Inc. as the contract research organization (CRO) for its Phase 1 clinical trial.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.

Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol ® Cyclo™ in Niemann-Pick Type C1.

PhaseBio to host conference call today at 5:30 am PST / 8:30 am EST that it has entered into an exclusive licensing agreement with Alfasigma S.p.A.

Cullgen Announces Prominent Publication by Cullgen Co-Founders Jian Jin and Yue Xiong in Nature Reviews Cancer

Turning Point Therapeutics, Inc. today announced that TPX-0022, the company’s inhibitor of MET has been granted orphan drug designation by the Food and Drug Administration (FDA) for the treatment of patients with gastric cancer.

Agenus Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted Agenus’ Biologics License Application (BLA) for balstilimab.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that its intellectual property portfolio around its lead Phase 3 candidate, Iomab-B, has been further strengthened internationally. In the EU, Actinium has been issued a patent covering the composition and methods administration of Iomab-B, an Antibody Radiation Conjugate (ARC) comprised of apamistamab

AcelRx Pharmaceuticals, Inc. , today announced it has reached agreement with the Food and Drug Administration (FDA) with regards to finalizing corrective actions in a warning letter.